GO:0005862 muscle thin filament tropomyosin: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005862 describes the tropomyosin dimer specifically associated with actin and the troponin complex in muscle thin filaments [1,2].
• Tropomyosin is a coiled-coil dimer that binds along actin filaments and regulates myosin binding in a calcium-dependent manner [3,6].
• The thin filament acts as a molecular switch: troponin and tropomyosin block myosin-binding sites in relaxed muscle and expose them upon calcium binding [2,8].
• Tropomyosin pivoting and cooperative activation are essential for normal muscle contraction and relaxation [1,4,5,7].
• Mutations in thin filament proteins, including tropomyosin, are linked to cardiomyopathies and skeletal myopathies.
• CRISPR-based models (knockout, point mutation, knock-in) enable precise dissection of tropomyosin function in health and disease.
Description
GO:0005862, muscle thin filament tropomyosin, is a cellular component term that defines a specific form of the tropomyosin dimer found in association with actin and the troponin complex in muscle thin filaments [1,2]. Tropomyosin is an alpha-helical coiled-coil protein that polymerizes head-to-tail along the actin filament and, together with troponin, regulates the interaction between actin and myosin in striated muscle [3,6]. This term is distinct from non-muscle tropomyosin isoforms and is critical for understanding the structural and regulatory basis of muscle contraction. Researchers studying muscle physiology, cardiomyopathies, and myopathies rely on this term to annotate proteins and complexes that localize to the thin filament regulatory unit [2,8]. The thin filament is a highly ordered assembly of actin, tropomyosin, and troponin, and its function depends on precise conformational changes that are still being resolved at atomic resolution [1,5]. Understanding GO:0005862 is therefore essential for interpreting genetic variants, designing functional assays, and developing therapeutic strategies targeting muscle contractility.
muscle thin filament tropomyosin At A Glance
| GO ID | GO:0005862 |
|---|---|
| GO term | muscle thin filament tropomyosin |
| Ontology | cellular_component |
| Synonym | None |
| Major function | Regulates actin-myosin interaction in muscle contraction via calcium-dependent conformational changes [2,8] |
| Associated proteins | Actin, troponin complex (TnC, TnI, TnT), myosin [1,6] |
| Location | Striated muscle thin filaments (cardiac and skeletal) [3,7] |
| Disease relevance | Cardiomyopathies, skeletal myopathies, and contractile dysfunction |
What Is GO:0005862?
According to the Gene Ontology, GO:0005862 (muscle thin filament tropomyosin) refers to a form of the tropomyosin dimer that is specifically associated with actin and the troponin complex in muscle thin filaments. This definition distinguishes the muscle-specific tropomyosin from other tropomyosin-containing structures and highlights its role as an integral component of the thin filament regulatory machinery.
Why Is muscle thin filament tropomyosin Important in Cell Biology?
GO:0005862 is important because it defines the molecular context in which tropomyosin functions as a gatekeeper of muscle contraction. The thin filament tropomyosin dimer, together with troponin, forms the regulatory switch that responds to calcium signals to either block or expose myosin-binding sites on actin [2,8]. This process is fundamental to cardiac and skeletal muscle physiology, and its dysregulation leads to severe diseases such as hypertrophic cardiomyopathy and nemaline myopathy. Moreover, understanding the structural dynamics of this complex is essential for drug discovery and for interpreting genetic variants identified in patients [1,5].
• Defines the muscle-specific tropomyosin dimer essential for calcium-dependent regulation of contraction [2,8].
• Mutations in thin filament proteins cause inherited cardiomyopathies and myopathies.
• Tropomyosin pivoting and cooperative activation are key to understanding muscle mechanics [1,4,5,7].
• Provides a target for therapeutic modulation of contractility in heart failure.
• Enables precise annotation of proteins in muscle thin filament structures [1,2].
• Facilitates comparative studies between cardiac and skeletal muscle isoforms [3,7].
• Supports structural biology efforts to resolve thin filament conformations [1,5].
• Guides CRISPR-based disease modeling of tropomyosin variants.
Structure and Composition of muscle thin filament tropomyosin
Tropomyosin dimer and coiled-coil structure
In simple terms: Tropomyosin is a long, rope-like protein made of two twisted strands.
The muscle thin filament tropomyosin is a parallel dimer of alpha-helical chains that form a coiled-coil structure. This dimer binds head-to-tail along the actin filament, spanning seven actin monomers and providing structural continuity. The coiled-coil is interrupted by periodic alanine residues that confer flexibility, allowing tropomyosin to adopt different positions on actin [3,6].
Association with actin and troponin complex
In simple terms: Tropomyosin sits on actin and interacts with troponin, a calcium-sensitive switch.
In the thin filament, tropomyosin associates with actin and the troponin complex (troponin C, I, and T) [2,8]. Troponin T anchors the complex to tropomyosin, while troponin I inhibits actin-myosin interaction in the absence of calcium [4,8]. Calcium binding to troponin C triggers conformational changes that move tropomyosin away from myosin-binding sites on actin [2,5].
Thin filament regulatory unit
In simple terms: The thin filament is a repeating unit of actin, tropomyosin, and troponin.
The regulatory unit of the thin filament consists of seven actin monomers, one tropomyosin dimer, and one troponin complex [6,7]. This arrangement allows cooperative activation: tropomyosin molecules influence each other's position, propagating conformational changes along the filament [6,7]. Structural studies have revealed that tropomyosin exists in blocked, closed, and open states depending on calcium and myosin binding [1,2,5].
Isoform diversity and tissue specificity
In simple terms: Different tropomyosin genes produce isoforms for different muscle types.
Muscle tropomyosin isoforms are encoded by TPM1, TPM2, TPM3, and TPM4, with TPM1 and TPM2 predominantly expressed in cardiac and skeletal muscle [3,7]. Alternative splicing generates tissue-specific variants that fine-tune contractile properties. The muscle thin filament tropomyosin term specifically refers to the isoforms localized to striated muscle thin filaments [1,2].
Key Genes Involved in GO:0005862 muscle thin filament tropomyosin
The following genes encode proteins that constitute or regulate the muscle thin filament tropomyosin complex.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TPM1 | Alpha-tropomyosin in cardiac and skeletal muscle | Mutations linked to hypertrophic cardiomyopathy and dilated cardiomyopathy |
| TPM2 | Beta-tropomyosin in slow skeletal and cardiac muscle | Associated with nemaline myopathy and cap disease |
| TPM3 | Slow skeletal muscle tropomyosin | Mutations cause nemaline myopathy |
| TPM4 | Tropomyosin 4, expressed in various tissues | Less studied in muscle but may modulate thin filament function |
| ACTA1 | Alpha-skeletal actin | Major component of thin filament; mutations cause actin myopathies |
| ACTC1 | Alpha-cardiac actin | Cardiac thin filament protein; mutations in cardiomyopathy |
| TNNT2 | Cardiac troponin T | Anchors troponin to tropomyosin; mutations in cardiomyopathy |
| TNNI3 | Cardiac troponin I | Inhibitory subunit; mutations in cardiomyopathy [4,8] |
| TNNC1 | Cardiac troponin C | Calcium-binding subunit; mutations in cardiomyopathy |
| MYH7 | Beta-myosin heavy chain | Interacts with thin filament; mutations in cardiomyopathy [5,8] |
| MYBPC3 | Myosin-binding protein C | Modulates thin filament activation; mutations in cardiomyopathy |
| ACTN2 | Alpha-actinin-2 | Z-disc protein that anchors thin filaments |
| NEB | Nebulin | Regulates thin filament length in skeletal muscle |
| TMOD1 | Tropomodulin-1 | Caps pointed ends of thin filaments |
| CAPZA1 | F-actin capping protein | Regulates actin dynamics in muscle |
| LEIOMODIN | Leiomodin | Nucleates actin polymerization in thin filaments |
| FHOD3 | Formin homology 2 domain containing 3 | Required for thin filament assembly in cardiomyocytes |
How Is muscle thin filament tropomyosin Regulated?
The muscle thin filament tropomyosin complex is regulated primarily by calcium binding to troponin C, which triggers a series of conformational changes that move tropomyosin from the blocked state to the closed and open states, allowing myosin to bind actin [2,5,8]. This process is highly cooperative, with tropomyosin molecules influencing each other's position along the filament [6,7]. Additionally, post-translational modifications such as phosphorylation of troponin I and T can modulate calcium sensitivity [4,8]. Myosin binding itself further stabilizes the open state, creating a positive feedback loop that enhances contraction [1,5].
muscle thin filament tropomyosin and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TPM1 | Hypertrophic cardiomyopathy, dilated cardiomyopathy | Knock-in of patient mutations in iPSC-derived cardiomyocytes |
| TPM2 | Nemaline myopathy, cap disease | Knockout in skeletal muscle cell lines or mouse models |
| TPM3 | Nemaline myopathy | Point mutation knock-in in C2C12 myoblasts |
| TNNT2 | Hypertrophic cardiomyopathy | CRISPR knockout in human iPSCs followed by cardiomyocyte differentiation |
| ACTC1 | Dilated cardiomyopathy | Overexpression of mutant actin in cardiomyocytes |
Cardiomyopathies
Mutations in genes encoding thin filament proteins, including TPM1, TNNT2, TNNI3, and ACTC1, are well-established causes of hypertrophic cardiomyopathy and dilated cardiomyopathy. These mutations often alter calcium sensitivity or cooperative activation, leading to impaired relaxation or hypercontractility [2,8]. Structural studies of mutant thin filaments have provided insights into how specific residues disrupt tropomyosin movement [1,4].
Skeletal myopathies
Mutations in TPM2, TPM3, and ACTA1 cause nemaline myopathy and other congenital myopathies characterized by muscle weakness and structural abnormalities. These mutations frequently affect tropomyosin's ability to bind actin or interact with troponin, resulting in dysregulated contraction [3,7].
Therapeutic implications
Understanding the precise conformational changes of tropomyosin has led to efforts to develop small molecules that modulate thin filament activity. For example, calcium sensitizers and desensitizers are being explored for heart failure treatment. CRISPR-based disease models are invaluable for testing these compounds and dissecting mutation-specific effects.
From muscle thin filament tropomyosin-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a TPM1 variant alter calcium sensitivity? | Point mutation knock-in in iPSC-derived cardiomyocytes |
| What is the effect of TPM2 loss on sarcomere structure? | Knockout in skeletal muscle cell lines (e.g., C2C12) |
| How does a tropomyosin mutation affect cooperative activation? | Knock-in of mutant TPM1 in mouse models |
| Can a drug rescue thin filament dysfunction? | Overexpression of wild-type or mutant tropomyosin in cardiomyocytes |
| What proteins interact with muscle tropomyosin? | Tagged knock-in (e.g., GFP-TPM1) for affinity purification |
| How do isoforms differ in function? | CRISPR-mediated isoform-specific knockout in cell lines |
How to Study the muscle thin filament tropomyosin Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cryo-EM | 3D structure of thin filament at near-atomic resolution | Visualizing tropomyosin states [1,5] |
| In vitro motility assay | Movement of actin filaments over myosin | Functional impact of tropomyosin mutations |
| Actin-myosin ATPase assay | ATP hydrolysis rate | Regulation by tropomyosin/troponin |
| FRET | Distance changes between probes on tropomyosin and actin | Real-time conformational dynamics |
| CRISPR knockout | Loss of protein function | Determining essentiality of tropomyosin isoforms |
| CRISPR knock-in | Introduction of specific mutations | Modeling patient variants |
| Immunofluorescence | Localization of thin filament proteins | Sarcomere integrity assessment |
| Co-immunoprecipitation | Protein-protein interactions | Identifying novel thin filament components |
Structural biology (cryo-EM, X-ray crystallography)
High-resolution structures of the thin filament have revealed the atomic details of tropomyosin position and movement [1,2,5]. Cryo-electron microscopy has been particularly powerful in capturing different states of the thin filament [1,5].
In vitro motility and actin-myosin ATPase assays
These assays measure the functional consequences of tropomyosin mutations on myosin binding and ATPase activity [6,7]. They are often used to validate structural findings and test the effects of post-translational modifications.
Fluorescence resonance energy transfer (FRET)
FRET can monitor tropomyosin position on actin in real time, providing dynamic information about the blocked, closed, and open states [3,6].
CRISPR-based genome editing
CRISPR/Cas9 allows precise introduction of disease-associated mutations into cell lines and iPSCs, enabling functional studies in a relevant genetic context.
How CRISPR Can Be Used to Study GO:0005862 muscle thin filament tropomyosin
Knockout
CRISPR knockout of TPM1, TPM2, or TPM3 in cell lines or iPSCs can reveal their essential roles in sarcomere assembly and function. Complete knockout often causes severe defects, but conditional or isoform-specific knockouts allow more nuanced studies.
Point Mutation
Introducing patient-specific point mutations (e.g., TPM1 E62Q, TPM2 K7del) via CRISPR base editing or homology-directed repair enables precise modeling of cardiomyopathy and myopathy. These models are crucial for understanding mutation-specific effects on calcium sensitivity and cooperativity [1,4].
Knock-in
Knock-in of tagged tropomyosin (e.g., GFP or HA) allows live-cell imaging and biochemical purification of the thin filament complex. This approach is valuable for studying tropomyosin dynamics in real time.
Overexpression
Overexpression of wild-type or mutant tropomyosin in cardiomyocytes or skeletal muscle cells can be used to assess dominant-negative effects and rescue experiments. It is particularly useful when endogenous protein levels are limiting.
How EDITGENE Supports muscle thin filament tropomyosin Research
Researchers studying muscle thin filament tropomyosin-related genes often need to determine whether a candidate gene is causally involved in contractile function or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery process, from knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for muscle thin filament tropomyosin research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| TPM3 Knockout HEK293 Cell Line | EDJ-KQ1710 | Human | 7170 | Details Get a Quote |
| TPM4 Knockout HEK293 Cell Line | EDJ-KQ2908 | Human | 7171 | Details Get a Quote |
| TPM1 Knockout HEK293 Cell Line | EDJ-KQ5956 | Human | 7168 | Details Get a Quote |
| TPM2 Knockout HEK293 Cell Line | EDJ-KQ15895 | Human | 7169 | Details Get a Quote |
| TPM4 Knockout A-549 Cell Line | EDJ-KQ23993 | Human | 7171 | Details Get a Quote |
| TPM4 Knockout HCT 116 Cell Line | EDJ-KQ23994 | Human | 7171 | Details Get a Quote |
| TPM4 Knockout HeLa Cell Line | EDJ-KQ23995 | Human | 7171 | Details Get a Quote |
| TPM2 Knockout A-549 Cell Line | EDJ-KQ49115 | Human | 7169 | Details Get a Quote |
| TPM2 Knockout HCT 116 Cell Line | EDJ-KQ49116 | Human | 7169 | Details Get a Quote |
| TPM2 Knockout HeLa Cell Line | EDJ-KQ49117 | Human | 7169 | Details Get a Quote |
| TPM3 Knockout A-549 Cell Line | EDJ-KQ22865 | Human | 7170 | Details Get a Quote |
| TPM3 Knockout HCT 116 Cell Line | EDJ-KQ22866 | Human | 7170 | Details Get a Quote |
| TPM3 Knockout HeLa Cell Line | EDJ-KQ22867 | Human | 7170 | Details Get a Quote |
| TPM1 Knockout A-549 Cell Line | EDJ-KQ29516 | Human | 7168 | Details Get a Quote |
| TPM1 Knockout HCT 116 Cell Line | EDJ-KQ29517 | Human | 7168 | Details Get a Quote |
Displaying Records 1 To 15 Of 18 Records
Frequently Asked Questions About muscle thin filament tropomyosin
What is GO:0005862?
GO:0005862 is the Gene Ontology term for muscle thin filament tropomyosin, a form of the tropomyosin dimer found associated with actin and the troponin complex in muscle thin filaments [1,2].
What genes are involved in muscle thin filament tropomyosin?
Key genes include TPM1, TPM2, TPM3, TPM4, ACTA1, ACTC1, TNNT2, TNNI3, and TNNC1 [3,7,8].
What is the function of tropomyosin in muscle?
Tropomyosin regulates the interaction between actin and myosin in a calcium-dependent manner, acting as a gatekeeper of muscle contraction [2,8].
How does tropomyosin move during muscle contraction?
Calcium binding to troponin C causes tropomyosin to pivot from the blocked state to the closed and open states, exposing myosin-binding sites on actin [1,5].
What diseases are associated with tropomyosin mutations?
Mutations in TPM1, TPM2, and TPM3 are linked to hypertrophic cardiomyopathy, dilated cardiomyopathy, and nemaline myopathy.
What is the structure of the muscle thin filament?
The thin filament is composed of actin, tropomyosin, and the troponin complex in a repeating regulatory unit [6,7].
How can I study tropomyosin function using CRISPR?
CRISPR knockout, point mutation knock-in, and tagged knock-in in muscle cell lines or iPSCs allow precise functional studies.
What is the role of troponin in thin filament regulation?
Troponin transduces calcium signals to tropomyosin, controlling its position on actin and thus muscle contraction [2,4,8].
What are the different states of tropomyosin on actin?
Tropomyosin exists in blocked, closed, and open states, corresponding to different levels of myosin binding [1,2,5].
Why is cooperative activation important in thin filaments?
Cooperative activation allows a small calcium signal to trigger a coordinated switch along the thin filament, ensuring efficient contraction [6,7].
Conclusion
GO:0005862 muscle thin filament tropomyosin is a central component of the muscle contractile apparatus, serving as the regulatory interface between calcium signaling and force generation. Its precise conformational dynamics, governed by interactions with actin and troponin, are critical for normal muscle function, and their disruption leads to severe cardiac and skeletal myopathies. Continued research using advanced structural and CRISPR-based approaches will further illuminate the molecular basis of these diseases and aid in the development of targeted therapies.
References
- 1. Lehman W et al.. 2023. Troponin-I-induced tropomyosin pivoting defines thin-filament function in relaxed and active muscle.. J Gen Physiol 155(7) PMID: 37249525
- 2. Yamada Y et al.. 2020. Cardiac muscle thin filament structures reveal calcium regulatory mechanism.. Nat Commun 11(1):153 PMID: 31919429
- 3. El-Mezgueldi M. 2014. Tropomyosin dynamics.. J Muscle Res Cell Motil 35(3-4):203-10 PMID: 24510226
- 4. Lehman W et al.. 2021. C-terminal troponin-I residues trap tropomyosin in the muscle thin filament blocked-state.. Biochem Biophys Res Commun 551:27-32 PMID: 33714756
- 5. Rynkiewicz MJ et al.. 2024. Myosin's powerstroke transitions define atomic scale movement of cardiac thin filament tropomyosin.. J Gen Physiol 156(5) PMID: 38607351
- 6. Lehman W et al.. 2013. Gestalt-binding of tropomyosin on actin during thin filament activation.. J Muscle Res Cell Motil 34(3-4):155-63 PMID: 23666668
- 7. Moore JR et al.. 2016. Structural determinants of muscle thin filament cooperativity.. Arch Biochem Biophys 594:8-17 PMID: 26891592
- 8. Tobacman LS. 2021. Troponin Revealed: Uncovering the Structure of the Thin Filament On-Off Switch in Striated Muscle.. Biophys J 120(1):1-9 PMID: 33221250
